FBT Biotech ETF Tops Category Returns, Outpaces IBB
FBT biotech ETF is up 20.35% YTD and 53.20% over one year, beating category averages and IBB. Its concentrated equal-weight 30-stock portfolio carries a 0.55% expense ratio and $2.9B AUM.
Amgen
CompanyCompany Profile
Amgen is a U.S. biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics for serious illnesses. It is headquartered in Thousand Oaks, California and has operated as a biotechnology pioneer since 1980.
- Website
- https://www.amgen.com
- Headquarters
- Thousand Oaks, California, USA
- Founded
- 1980
- Stock Ticker
- NASDAQ:AMGN
Related News
Patent Cliff: Blockbuster Drugs Worth Up to $500B Face Generic Competition
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
IBBQ vs IBB: Biotech ETFs Show Strong Returns but High Volatility
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
Amgen Leads Oncology Push With T-Cell Engagers as AI and Organoid Platforms Reshape Drug Development
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
AI, Integrated Models and Decentralized Designs Reshape Clinical Trial Execution
Sponsors are adopting AI-enabled tools, integrated operating models and decentralized designs to accelerate clinical trials. FDA and EMA guidance underscores sponsor accountability, while new modeling links integrated operations to higher program value.
Cue Biopharma Names Dominic Borie Chief Medical Officer and R&D Head
Cue Biopharma appointed Dominic Borie as chief medical officer and R&D head as it advances CUE-221 (Phase 2 data expected Q3 2026) and CUE-401 (Phase 1 start Q4 2026). He brings over 20 years of immunology and clinical development experience. The company recently raised $50M to support clinical development.
Biotech Pipeline Advances: Can-Fite at BIO 2026, Peptide Candidates Top 2,000, Arrowhead RNAi in Phase 3
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
Amgen Stock Slides 12.6% as Novo Nordisk Holds GLP-1 Lead
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
New GLP-1 Competition, FDA Approval, and Genomic Atlases Advance Drug Development
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778316 |
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) |
RECRUITING | PHASE3 |
| NCT07745907 |
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers |
RECRUITING | PHASE1 |
| NCT07737925 |
LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan |
NOT_YET_RECRUITING | PHASE2 |
| NCT07717814 |
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity |
COMPLETED | PHASE1 |
| NCT07700238 |
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07684235 |
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) |
RECRUITING | PHASE3 |
| NCT07684144 |
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07637513 |
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07614776 |
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration |
RECRUITING | PHASE3 |
| NCT07598825 |
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis |
NOT_YET_RECRUITING | PHASE3 |